NEW YORK, Feb 14 – Gemini Genomics said Wednesday it recorded revenues of $72,000 in fiscal third-quarter 2001, compared with zero revenues in the year earlier quarter, as the result of license fees stemming from the company’s osteoporosis diagnostic effort.

Research and development costs for the quarter totaled $3.3 million, compared with $3.0 million, in the year ago quarter. During the quarter, Gemini of Cambridge, UK, accelerated its clinical and research efforts and expanded its research staff.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Robert Redfield is floated as the next director of the US Centers for Disease Control and Prevention, the Washington Post reports.

The New York Times writes that the National Institutes of Health's All of Us Research Program is "ambitious" and that some are concerned it might be overly so.

Representative Lamar Smith's criticism of the National Science Foundation has "changed the nature of the conversation," according to ScienceInsider.

In PLOS this week: non-coding RNA function in yeast, transcriptomic profiles of malaria parasites, and more.